As a reliable partner for new drug developers, medicinal chemistry service provided by biomaxlab encompasses a broad breath of chemistry services. We meet our clients’ needs using our strong expertise in organic and medicinal chemistry, extensive experience in industrial drug discovery and excellent managerial skills acquired from working experience at CRO. Each of our R&D services can be contracted as part of an integrated program or as a stand-alone project.
Medicinal Chemistry
biomaxlab’s medicinal chemistry experts can help devise medicinal chemistry strategies for clients’ need from hit identification, hit to lead generation to lead optimization. With our flexible tactics, we help start-up drug discovery units swiftly address their needs in medicinal chemistry and execute the medicinal chemistry strategies using our strong knowledge and experience in industrial drug discovery and managing CRO resources.
- Novel scaffold design and comparative analysis for hit identification
- Competitive landscape analysis for new programs
- Route design and exploration of structural diversity within new scaffolds
- IP analysis
- Assess HTS hit sets and design library for SAR profiling
- SAR analysis based on both in vitro and in vivo data
- Design initial leads from competitors‘ patents
- Focused library design for lead generation and optimization
- Design SPR-guided analogs with better drug-likeness
- Studies flow design and project consultation
- Help client identify and manage CRO resources
- Assisting patent filing for/by clients
Modern Synthetic Chemistry
- Organometallic chemistry (Highly reactive metal catalysis, reaction under inert atmosphere)
- Organoboron chemistry (Hydroboration and coupling, widely applied in material science and medicinal chemistry)
- Organofluorine chemistry
- Asymmetric synthesis (Catalysis and Resolution)
- Glycosylation (Important chemistry for biologically active compounds)
- Natural products modification( Common method to improve the medicinal and biological properties of natural products)
Custom Synthesis
Our chemists are experts in the latest technologies in synthetic organic chemistry, including asymmetric synthesis. We have a strong track-record and expertise in designing and preparing multi-step targets on scales ranging from milligrams to several hundred grams. Using this experience, we can handle custom syntheses of small molecules with novel scaffolds and functions.
- Bioassay substrates
- Building blocks and intermediates
- Chiral compounds
- Heterocyclic chemistry and scaffolds
- Multi-step synthesis
- Pharmaceutical reference standards (APIs, impurities, metabolites and parent compounds)
- Stable isotope labeled compounds (Deuterium, carbon-13, nitrogen-15 and oxygen-18)
- Synthesis route design
- Reaction condition optimization
- Scale-up (milligrams to kilograms)
biomaxlab screening service utilizes tailored assays to meet the demands of your screening strategies. We have the capacity and expertise to maximize your library screening efforts. Our services can be used for target validation, hit identification and lead optimization, or follow-up studies, choosing from our broad portfolio of assays for targets such as profiling of the cancer pathways, GPCRs, and ion channels. For these target screenings, we offer the flexibility of multiple readouts for luminescence assay and/or second messenger detection.
biomaxlab carries over 150 human and animal cell lines, see Table. Our assays can therefore be readily customized in primary, stably transfected, immortalized, cancer, and other cell types to meet your needs.
Assay Validation
Our assays are validated based on the NIH Chemical Genomics Center Assay Guidance Manual. Appropriate controls are included on every plate and Z' values and signal to noise calculations are determined for the entire screening process. Any assay that does not meet our specifications or specific criteria set by the customer will be repeated.
Our services deliver
- Bioanalytical screening of library compounds
- Final lead compounds
- High quality data
- Extensive validation and appropriate controls included
- Fast turnaround time depending on the size of the project
- Competitive pricing
- Complete confidentiality
G-protein-coupled receptors (GPCRs) draw much attention as drug targets because more than 40% of the approximately 500 clinically marketed drugs are targeting GPCRs. Functional assays for GPCRs are indispensable platforms for drug screening and ligand hunting. We provide assay systems which cover calcium flux, cAMP level and reporter assay for our customers to carry out high-throughput screening (HTS).
GPCRs transmit extracellular signals across the plasma membrane via intracellular coupling with heterotrimeric G proteins. Heterotrimeric G proteins are classified into four subfamilies based on their Gα subunits, Gs, Gi, Gq and G12. Current methods employed in GPCR screening assays measure G protein signaling by determining change in second messengers such as cAMP, inositol trisphosphate (IP3), and intracellular Ca2+ mobilizations, which demands different assay platforms and requires specialized instrumentation for each pathway which could be costly. Our proprietary GPCR assay platform is designed to report GPCR activation. These assays are used for potency rankings of GPCR modulators and for high throughput screening. The advantage of our GPCR screening assays is that they give you a cost-effective screening approach before you spend time and resource to narrow down individual GPCRs before you are not sure which subtypes of GPCRs are involved.
(TGFβ (TGF-beta), Wnt, NF-kB, MAPK)
BioMaxLab Reporter Assays provide a HTS for rapid, sensitive, and quantitative assessment of signal transduction pathway activation by measuring the activities of downstream transcription factors in cultured cells. We transfect the HEK-293 cells with the reporter and run services for the following signaling pathways to provide a comprehensive coverage for potential mechanism of action of drug candidates based on:
Monitor how the signaling pathway is regulated by your compounds.
Evaluate how potent the effect of tested compound is on activity of the pathway.
Delineate the potential biological targets for your drug candidates.
We have experimentally optimized the number of response elements as well as the intervening sequence between response elements to maximize the signal to noise ratio for each pathway.
In addition to the positive and negative controls included in each run, we also cotransfect the reporter with Renilla luciferase as an internal control for normalizing transfection efficiencies, monitoring cell viability and producing a ratiometric readout, thus to ensure the validity and the comparability of the data over time.
quanto costa cialis 20 mg, Acquisto Brand Viagra Senza Ricetta, acquistare levitra generico italiaAbsorption Study (CaCo-2):
Our absorption study model is designed to classify the absorption potential of our customers' compounds. We use Caco-2 cell monolayers to predict intestinal drug absorption. We routinely run assays for our customers that determine active and passive transport of a compound across cell monolayers.
Distribution Study: Cell permeability and efflux assays (MDR1-MDCKII):
The P-gp transporter is an efflux transporter that is encoded by the ABCB1 gene. P-gp is also known as P-glycoprotein and the Multi-Drug Resistance transporter 1 (MDR1). P-gp (MDR1) is expressed in many tissues of the body including in the kidney on the apical side of the intestinal lumen, the apical side of the bile canaliculus in liver hepatocytes, the apical membrane of proximal tubule epithelial cells and the apical side of the capillaries in the blood brain barrier (BBB). P-gp (MDR1) serves to limit the absorption of substrates, protect them from entering the brain and also to mediate their renal and hepatic elimination.
Human P-gp (MDR1) is known to be a determinant of drug absorption, distribution, and excretion of a number of clinically important drugs. P-gp is widely expressed in major organs, and, more specifically, P-gp is highly expressed in the capillaries of the blood brain barrier (BBB) and poses a barrier to brain penetration of its substrates. Given that P-gp efflux liability can be a major hurdle for CNS therapeutic drugs to cross the BBB and reach the target, the interactions of CNS compounds with P-gp may lead to the lack of CNS activity as a result of the decreased brain penetration. Thus, the prediction and understanding of the relevance of P-gp-mediated efflux transport have become important activities in the discovery and development of CNS drugs. Transwell-based assays using polarized MDCKII and MDR1-MDCKII cell lines provide a great tool to classify compounds as P-gp substrates. Comparison of the efflux ratios between MDR1-MDCKII and MDCKII transwell assays can provide a measure of the specific human P-gp-mediated efflux activity.
- Apical vs. Basolateral permeability (Caco-2, pH 6.5/7.4)
- Apical vs. Basolateral permeability (Caco-2, pH 7.4/7.4)
- Apical vs. Basolateral permeability (Caco-2, pH 7.4/7.4 + verapamil)
- Apical vs. Basolateral permeability (MDCKII, pH 7.4/7.4)
- Apical vs. Basolateral permeability (MDR1-MDCKII, pH 7.4/7.4)
- Apical vs. Basolateral permeability (MDR1-MDCKII, pH 7.4/7.4 + verapamil)
- Basolateral vs. Apical permeability (Caco-2, pH 6.5/7.4)
- Basolateral vs. Apical permeability (Caco-2, pH 7.4/7.4)
- Basolateral vs. Apical permeability (Caco-2, pH 7.4/7.4 + verapamil)
- Basolateral vs. Apical permeability (MDCKII, pH 7.4/7.4)
- Basolateral vs. Apical permeability (MDR1-MDCKII, pH 7.4/7.4)
- Basolateral vs. Apical permeability (MDR1-MDCKII, pH 7.4/7.4 + verapamil)
Drug-drug interactions involves inhibition and/or induction of drug metabolizing enzymes. Inhibition of drug metabolizing enzymes is a major mechanism of drug-drug interactions. The majority of these enzymes are CYPs.
CYP Inhibition Studies
These studies are conducted with HLM or recombinant enzymes, FDA-accepted probe substrates, and control inhibitors. Both IC50 and Ki values can be determined, and the pre-incubation of the test article with microsomes and NADPH are used to assess time-dependent inhibition. Alternatively, we can use recombinant CYP450 enzymes with fluorogenic probe substrates in screening assays.
UGT Inhibition Studies
Recombinant UGT enzymes are used to assess the IC50 values of a test article with respect to the most common isoforms.
CYP Induction Studies
Enzyme induction following drug administration can lead to enhanced clearance of co-medications or itself, causing a drug-drug interaction, therapeutic failure, patient management, and potentially other safety issues. Cryopreserved human hepatocytes from one or more donors are used to assess the potential of a compound to induce the activity of a drug metabolizing CYP. In addition to directly studying enzyme activity, we are also able to determine CYP mRNA or protein expression induction using RT-PCR or Western Analysis, respectively (two FDA-accepted validation methods) upon request by the clients.
cialis en pharmacie, levitra acheter, lioresal, viagra en venteIn Vivo Pharmacokinetic/ADME Screening
Whether you have one compound or a library of compounds requiring DMPK assessment, our well-trained and proficient scientists at BioMaxLab can design, conduct, and interpret the DMPK components of your program as part of our streamlined screening services. Quick study initiation, multiple species, resident animal colonies with chronic surgical models included, and various dose regimens and administration routes plus bioanalytical support provide the necessary tools you need to rapidly identify and optimize your potential drug candidates.
Available services:
-
Tissue distribution
-
Metabolite profiling and identification
-
Single/multiple/cassette dosing
-
Bioavailability and bioequivalence
The hERG channel plays a significant role in cardiac repolarization and acute hERG block alone will prolong QT and induce Torsades de Pointes. Compounds routinely affect The hERG channel influencing the effect of hERG block. BioMaxLab provides a fast, comprehensive preclinical cardiac safety assessment for full resolution of potential cardiac risk prior to IND submission. Multiple assays are employed to assess a compound's effect on preclinical cardiac safety at molecular, cellular, tissue and system levels. We enable you to achieve nearly 100% predictivity of cardiac risk with our preclinical cardiac safety assessment. BioMaxLab provides the most complete preclinical cardiac safety package presently available.
hERG Channel Electrophysiology Overview
Drug-induced delayed cardiac repolarization has associated with block of hERG (a functionally prominent ventricular repolarizing potassium current) and is linked to cardiac proarrhythmia (Torsades-de-Pointes). However, hERG current block is not always associated with delayed repolarization, and preclinical cardiac safety studies evaluating only hERG current provide a focused but narrow perspective. Additional cardiac ion channels represent numerous potential off-target effects that may modulate the effects of hERG current block, affect impulse initiation (chronotropic effects), conduction (dromotropic effects), or contractility (inotropic effects). Routine hERG screening in early discovery efforts should be supplemented with additional studies to avoid unduly discarding hERG blocking drugs not affecting delayed repolarization and to ensure overall cardiac safety.
Assessing hERG Channel Inhibition
- BioMaxLab uses manual patch clamp (a gold standard) to assess hERG channel inhibition on HEK293 cells or CHO cells stably transfected with the hERG ion channel.
- BioMaxLab uses manual patch clamp (a gold standard) to assess hERG channel inhibition on HEK293 cells or CHO cells stably transfected with the hERG ion channel.
- Protocols include exploratory non-GLP screening of single high concentration or IC50.
- Validated with a number of agents known to affect the hERG current, including terfenadine, cisapride and E-4031.
The BioMaxLab Difference
- A customer focused approach, delivering beyond your expectations.
- Scientific excellence with over 20 years combined experience in in vitro pharmacology and a technical team with the same high standards as yours.
- A quality service.
- A flexible service; we support a cross-section of global clients, from small biotech to large pharmaceutical companies, and academia, providing both validated assays and tailored protocols.
BioMaxLab offers Cancer Cell Line Screening of over 150 Cancer Cell Lines Table. Cell lines are of human origin and are well characterized. You can also select cancer cells from our cancer cell-58 panel (CCP-58) that is similar to those included in the NCI-60 Panel of cancer cell lines or clients are welcome to design a special panel of cells that is most relevant to their specific research need. We will assist you with the selection of cell lines by tissue of origin or for the presence of specific gene mutations responsible for cancer induction or responsible for drug resistance.
CCP-58 panel
The CCP-58 panel is a set of 58 representative human cancer cell lines derived from diverse tissues; brain, blood and bone marrow, breast, colon, kidney, lung, ovary, prostate and skin. Researchers across the world have employed these cell lines to characterize drug effectiveness.
Flexibility
BioMaxLab has adopted a very flexible, screening approach with multiple end point parameters available including proliferation or other assays (e.g. ion channels) in the medium conditions of interest.
- 96-well screening plate format
- 3 to 4 weeks data turnaround time
- Choice of proliferation assay method (Alamar blue, CyQuant, XTT, MTS)
hERG Channel Electrophysiology Overview
Drug-induced delayed cardiac repolarization has associated with block of hERG (a functionally prominent ventricular repolarizing potassium current) and is linked to cardiac proarrhythmia (Torsades-de-Pointes). However, hERG current block is not always associated with delayed repolarization, and preclinical cardiac safety studies evaluating only hERG current provide a focused but narrow perspective. Additional cardiac ion channels represent numerous potential off-target effects that may modulate the effects of hERG current block, affect impulse initiation (chronotropic effects), conduction (dromotropic effects), or contractility (inotropic effects). Routine hERG screening in early discovery efforts should be supplemented with additional studies to avoid unduly discarding hERG blocking drugs not affecting delayed repolarization and to ensure overall cardiac safety.
Assessing hERG Channel Inhibition
- BioMaxLab uses manual patch clamp (a gold standard) to assess hERG channel inhibition on HEK293 cells or CHO cells stably transfected with the hERG ion channel.
- BioMaxLab uses manual patch clamp (a gold standard) to assess hERG channel inhibition on HEK293 cells or CHO cells stably transfected with the hERG ion channel.
- Protocols include exploratory non-GLP screening of single high concentration or IC50.
- Validated with a number of agents known to affect the hERG current, including terfenadine, cisapride and E-4031.
The BioMaxLab Difference
- A customer focused approach, delivering beyond your expectations.
- Scientific excellence with over 20 years combined experience in in vitro pharmacology and a technical team with the same high standards as yours.
- A quality service.
- A flexible service; we support a cross-section of global clients, from small biotech to large pharmaceutical companies, and academia, providing both validated assays and tailored protocols.